Fulcrum Therapeutics Names Robert Gould As Interim CEO After CEO Bryan Stuart Departs

RTTNews | il y a 940
Fulcrum Therapeutics Names Robert Gould As Interim CEO After CEO Bryan Stuart Departs

(RTTNews) - Biopharmaceutical company Fulcrum Therapeutics, Inc. (FULC) announced Wednesday that Robert Gould, former president and founding chief executive officer, has been appointed as interim CEO, effective January 3, 2023. He is also a current member of the Board of Directors.

Gould succeeds Bryan Stuart, who departs to pursue other opportunities. Fulcrum's Board of Directors has initiated a search for a permanent CEO.

Gould has over 35 years of biopharmaceutical industry and management experience. He served as founding president and CEO of Fulcrum from 2016 to 2021, after which he remained a member of the Board of Directors. Before Fulcrum, he served as president and CEO of Epizyme from 2010 to 2015.

Before that, Gould spent more than 20 years at Merck in leadership positions of increasing responsibility, culminating in the role of vice president, licensing, and external research.

Meanwhile, Stuart was serving as president and CEO of Fulcrum since March 2021. He joined Fulcrum as chief operating officer in 2018. Prior to joining Fulcrum, Bryan was president and CEO of Yarra Therapeutics.

read more
U.S. Construction Spending Unexpectedly Sees Further Downside In June

U.S. Construction Spending Unexpectedly Sees Further Downside In June

The Commerce Department released a report on Friday unexpectedly showing a continued decrease by U.S. construction spending in the month of June. The report said construction spending fell by 0.4 percent to an annual rate of $2.136 trillion in June after sliding by 0.5 percent to a revised rate of $2.144 trillion in May.
RTTNews | il y a 17 minutes
U.S. Consumer Sentiment Improves Marginally Less Than Previously Estimated In July

U.S. Consumer Sentiment Improves Marginally Less Than Previously Estimated In July

Revised data released by the University of Michigan on Friday showed consumer sentiment in the U.S. improved marginally less than previously estimated in the month of July. The University of Michigan said its consumer sentiment index for July was downwardly revised to 61.7 from a preliminary reading of 61.8. Economists had expected the index to be upwardly revised to 62.0.
RTTNews | il y a 21 minutes
U.S. Manufacturing Index Unexpectedly Dips To Nine-Month Low In July

U.S. Manufacturing Index Unexpectedly Dips To Nine-Month Low In July

Manufacturing activity in the U.S. unexpectedly contracted at a slightly faster rate in the month of July, according to a report released by the Institute for Supply Management on Friday. The ISM said its manufacturing PMI edged down to 48.0 in July after inching up to 49.0 in June with a reading below 50 indicating contraction.
RTTNews | il y a 24 minutes
Eurozone Inflation Steady At 2% ECB Target

Eurozone Inflation Steady At 2% ECB Target

Euro area consumer price inflation was unchanged at the European Central Bank's 2 percent target in July, easing the pressure for more easing. The harmonized index of consumer prices increased 2.0 percent year-on-year in July, the same rate of increase as seen in June. Inflation was forecast to ease marginally to 1.9 percent.
RTTNews | il y a 1h 10min
Bay Street Likely To Open On Weak Note

Bay Street Likely To Open On Weak Note

Canadian shares are set to open on a negative note on Friday as U.S. President Donald Trump's announcement of fresh tariffs on Canada and several other countries has hurt investor sentiment across global markets.
RTTNews | il y a 2h 30min
FTSE 100 Down 0.55% As Trump's Tariff Moves Hurt Sentiment

FTSE 100 Down 0.55% As Trump's Tariff Moves Hurt Sentiment

U.K. stocks are down in negative territory on Friday, weighed down by trade concerns after U.S. President Donald Trump announced sweeping tariffs on several countries. The President's letters to 17 major pharma firms, urging them to cut prices, has triggered a sell-off in the pharmaceutical sector.
RTTNews | il y a 3h 39min